STAAR Surgical (NASDAQ:STAA) Stock Rating Lowered by William Blair

STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a research note issued to investors on Wednesday,Briefing.com Automated Import reports.

A number of other equities analysts have also recently issued reports on the stock. Stephens raised shares of STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. Canaccord Genuity Group reduced their price objective on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating on the stock in a research note on Monday, December 9th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $36.50.

STAAR Surgical Price Performance

Shares of STAAR Surgical stock opened at $21.88 on Wednesday. The firm has a market cap of $1.08 billion, a P/E ratio of 49.73 and a beta of 0.62. The firm has a 50 day simple moving average of $23.94 and a 200 day simple moving average of $29.33. STAAR Surgical has a fifty-two week low of $21.13 and a fifty-two week high of $52.68.

Insider Transactions at STAAR Surgical

In related news, major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the business’s stock in a transaction that occurred on Monday, December 16th. The shares were acquired at an average cost of $24.24 per share, with a total value of $1,296,840.00. Following the transaction, the insider now owns 10,821,931 shares of the company’s stock, valued at $262,323,607.44. The trade was a 0.50 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have bought a total of 105,876 shares of company stock valued at $2,487,168 over the last three months. 1.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On STAAR Surgical

Several institutional investors have recently added to or reduced their stakes in STAA. Truist Financial Corp bought a new stake in STAAR Surgical in the 2nd quarter valued at $268,000. Cetera Investment Advisers acquired a new stake in STAAR Surgical in the 2nd quarter valued at $1,135,000. Exchange Traded Concepts LLC increased its stake in STAAR Surgical by 17.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 30,020 shares of the medical instruments supplier’s stock valued at $1,115,000 after buying an additional 4,498 shares during the last quarter. Creative Planning increased its stake in STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after buying an additional 408 shares during the last quarter. Finally, nVerses Capital LLC increased its stake in STAAR Surgical by 78.3% in the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 1,800 shares during the last quarter. 96.70% of the stock is owned by institutional investors.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.